Cognition Therapeutics Inc (CGTX)

Cognition Therapeutics Inc (CGTX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $89.1M; returns 1 day +2.6%, 1 week -1.5%, 1 year -57.7%.

Cognition Therapeutics Inc. (CGTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule therapeutics for age-related neurodegenerative disorders. The company's lead product candidate, zervimesine (also known as CT1812), is an orally available sigma-2 receptor (σ-2) modulator.

Groups CGTX belongs to

• Clinical Stage Biotech
• Biotechnology
• Alzheimer's Disease
• Neuroscience
• CNS Disorders
• Drug Discovery
• Aging Population Needs
• Clinical Stage

CGTX financial model: income statement, cash flow and balance sheet